| Primary |
| Drug Use For Unknown Indication |
37.9% |
| Hypertension |
19.7% |
| Product Used For Unknown Indication |
18.1% |
| Type 2 Diabetes Mellitus |
3.7% |
| Cardiomyopathy |
2.7% |
| Hypercholesterolaemia |
2.4% |
| Myocardial Infarction |
2.1% |
| Depression |
1.6% |
| Diabetes Mellitus |
1.6% |
| Hypothyroidism |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Type 1 Diabetes Mellitus |
1.3% |
| Benign Prostatic Hyperplasia |
1.1% |
| Urticaria |
1.1% |
| Bronchitis |
0.8% |
| Pulmonary Embolism |
0.8% |
| Renal Transplant |
0.8% |
| Atrial Fibrillation |
0.5% |
| Cerebrovascular Accident Prophylaxis |
0.5% |
| Glioblastoma |
0.5% |
|
| Renal Failure Acute |
14.6% |
| Hypotension |
10.4% |
| Renal Failure |
10.4% |
| Jaundice Cholestatic |
6.3% |
| Nephrogenic Diabetes Insipidus |
6.3% |
| Orthostatic Hypotension |
6.3% |
| Coombs Positive Haemolytic Anaemia |
4.2% |
| Malaise |
4.2% |
| Pancytopenia |
4.2% |
| Pemphigoid |
4.2% |
| Skin Necrosis |
4.2% |
| Thrombocytopenia |
4.2% |
| Urinary Tract Infection |
4.2% |
| Weight Decreased |
4.2% |
| Acquired Epidermolysis Bullosa |
2.1% |
| Acute Generalised Exanthematous Pustulosis |
2.1% |
| Aphthous Stomatitis |
2.1% |
| Cerebrovascular Accident |
2.1% |
| Dermatitis Bullous |
2.1% |
| Erythema Multiforme |
2.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
47.2% |
| Hypertension |
15.7% |
| Product Used For Unknown Indication |
13.0% |
| Renal Transplant |
3.5% |
| Epilepsy |
2.4% |
| Myocardial Infarction |
2.0% |
| Depression |
1.6% |
| Hyperphosphataemia |
1.6% |
| Rhinitis |
1.6% |
| Atrial Fibrillation |
1.2% |
| Benign Prostatic Hyperplasia |
1.2% |
| Bronchitis |
1.2% |
| Erysipelas |
1.2% |
| Gastric Ulcer |
1.2% |
| Hypothyroidism |
1.2% |
| Prophylaxis |
1.2% |
| Embolism |
0.8% |
| Hypercholesterolaemia |
0.8% |
| Migraine With Aura |
0.8% |
| Prostatic Adenoma |
0.8% |
|
| Weight Decreased |
13.2% |
| Renal Failure Acute |
11.3% |
| Cerebrovascular Accident |
7.5% |
| Hypertension |
5.7% |
| Urinary Tract Infection |
5.7% |
| Aphthous Stomatitis |
3.8% |
| Haematuria |
3.8% |
| Haemolysis |
3.8% |
| Hypotension |
3.8% |
| Jaundice |
3.8% |
| Lung Disorder |
3.8% |
| Oesophageal Candidiasis |
3.8% |
| Orthostatic Hypotension |
3.8% |
| Pancytopenia |
3.8% |
| Poisoning Deliberate |
3.8% |
| Renal Tubular Disorder |
3.8% |
| Respiratory Arrest |
3.8% |
| Respiratory Distress |
3.8% |
| Transaminases Increased |
3.8% |
| Vomiting |
3.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
21.5% |
| Product Used For Unknown Indication |
20.5% |
| Hypertension |
17.9% |
| Hypothyroidism |
4.0% |
| Rheumatoid Arthritis |
3.6% |
| Atrial Fibrillation |
3.2% |
| Type 2 Diabetes Mellitus |
3.2% |
| Diabetes Mellitus |
2.7% |
| Cardiac Failure |
2.5% |
| Hypercholesterolaemia |
2.5% |
| Hyperlipidaemia |
2.5% |
| Osteoporosis |
2.5% |
| Hiv Infection |
2.1% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Dementia Alzheimer's Type |
1.9% |
| Prophylaxis |
1.9% |
| Asthma |
1.7% |
| Agitation |
1.3% |
| Breast Cancer Metastatic |
1.3% |
| Chronic Myeloid Leukaemia |
1.3% |
|
| Pyrexia |
9.0% |
| Renal Failure Acute |
7.7% |
| Weight Decreased |
7.7% |
| Cardiac Valve Disease |
6.4% |
| Transaminases Increased |
6.4% |
| Vomiting |
6.4% |
| International Normalised Ratio Increased |
5.1% |
| Rhabdomyolysis |
5.1% |
| Septic Shock |
5.1% |
| Carbon Monoxide Diffusing Capacity Decreased |
3.8% |
| Oesophageal Carcinoma |
3.8% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.8% |
| Pleural Effusion |
3.8% |
| Prothrombin Level Decreased |
3.8% |
| Renal Failure |
3.8% |
| Somnolence |
3.8% |
| Subdural Haematoma |
3.8% |
| Toxic Skin Eruption |
3.8% |
| Vascular Dementia |
3.8% |
| Angioedema |
2.6% |
|
| Interacting |
| Cardiomyopathy |
40.5% |
| Hypertension |
16.2% |
| Drug Use For Unknown Indication |
10.8% |
| Diabetes Mellitus |
9.5% |
| Benign Neoplasm Of Prostate |
5.4% |
| Essential Hypertension |
5.4% |
| Hypokalaemia |
5.4% |
| Ovarian Epithelial Cancer |
4.1% |
| Hypercholesterolaemia |
2.7% |
|
| Hyperkalaemia |
44.4% |
| Renal Failure |
33.3% |
| Drug Interaction |
11.1% |
| Rhabdomyolysis |
11.1% |
|
